Peak expiratory flow- and 6-minute walk test-based individualized management in elderly patients with chronic obstructive pulmonary disease: a retrospective analysis of cardiopulmonary function

Scritto il 22/11/2026
da Qian-Wen Cao

Am J Transl Res. 2026 Oct 15;18(10):9067-9077. doi: 10.62347/WHWX2009. eCollection 2026.

ABSTRACT

OBJECTIVE: To evaluate the association of peak expiratory flow (PEF) and 6-minute walk test (6MWT)-based management with disease severity and cardiopulmonary function in elderly patients with chronic obstructive pulmonary disease (COPD).

METHODS: This retrospective study included 128 elderly patients with stable COPD treated between December 2022 and August 2024. Patients received routine nursing (control, n = 64) or routine nursing plus individualized PEF/6MWT-based management (observation, n = 64). Symptoms, pulmonary function, arterial blood gas values, cardiac function, exercise capacity, inflammatory markers, and quality of life were assessed at baseline and after 12 weeks.

RESULTS: After intervention, the COPD Assessment Test (CAT), modified Medical Research Council (mMRC) score, arterial partial pressure of carbon dioxide (PaCO2), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), pulmonary artery systolic pressure (PASP), percentage of total 6MWT time with peripheral oxygen saturation (SpO2) below 88%, 90%, and 92% (T88, T90, and T92, respectively), maximum heart rate, Borg score, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) decreased significantly compared to baseline values (P < 0.05) and were lower in the observation group than in the control group (P < 0.05). In contrast, peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), FEV1/forced vital capacity (FEV1/FVC), arterial partial pressure of oxygen (PaO2), SpO2, left ventricular ejection fraction (LVEF), 6MWD, minimum SpO2 during exercise, and quality-of-life scores increased significantly after the intervention (P < 0.05) and were higher in the observation group than in the control group (P < 0.05).

CONCLUSION: In elderly patients with stable COPD, PEF- and 6MWT-based management was associated with improvements in clinical symptoms, cardiopulmonary function, exercise capacity, inflammatory status, and quality of life.

PMID:43068066 | PMC:PMC13788455 | DOI:10.62347/WHWX2009